Toxins 2011, 3(11), 1433-1452; doi:10.3390/toxins3111433

Antibodies against Anthrax: Mechanisms of Action and Clinical Applications

1 Unité de biotechnologie des anticorps et des toxines, Département de microbiologie, Institut de Recherche Biomédicale des Armées (IRBA-CRSSA), 38702 La Tronche Cedex, France 2 US Army Medical Research and Materiel Command, Fort Detrick, MD 21702, USA
* Author to whom correspondence should be addressed.
Received: 1 September 2011; in revised form: 3 November 2011 / Accepted: 7 November 2011 / Published: 16 November 2011
(This article belongs to the Special Issue Anthrax Toxin)
PDF Full-text Download PDF Full-Text [1088 KB, Updated Version, uploaded 25 November 2011 11:54 CET]
The original version is still available [1133 KB, uploaded 16 November 2011 11:26 CET]
Abstract: B. anthracis is a bioweapon of primary importance and its pathogenicity depends on its lethal and edema toxins, which belong to the A-B model of bacterial toxins, and on its capsule. These toxins are secreted early in the course of the anthrax disease and for this reason antibiotics must be administered early, in addition to other limitations. Antibodies (Abs) may however neutralize those toxins and target this capsule to improve anthrax treatment, and many Abs have been developed in that perspective. These Abs act at various steps of the cell intoxication and their mechanisms of action are detailed in the present review, presented in correlation with structural and functional data. The potential for clinical application is discussed for Abs targeting each step of entry, with four of these molecules already advancing to clinical trials. Paradoxically, certain Abs may also enhance the lethal toxin activity and this aspect will also be presented. The unique paradigm of Abs neutralizing anthrax toxins thus exemplifies how they may act to neutralize A-B toxins and, more generally, be active against infectious diseases.
Keywords: anthrax toxins; protective antigen; lethal factor; edema factor; antibodies

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Froude II, J.W.; Thullier, P.; Pelat, T. Antibodies against Anthrax: Mechanisms of Action and Clinical Applications. Toxins 2011, 3, 1433-1452.

AMA Style

Froude II JW, Thullier P, Pelat T. Antibodies against Anthrax: Mechanisms of Action and Clinical Applications. Toxins. 2011; 3(11):1433-1452.

Chicago/Turabian Style

Froude II, Jeffrey W.; Thullier, Philippe; Pelat, Thibaut. 2011. "Antibodies against Anthrax: Mechanisms of Action and Clinical Applications." Toxins 3, no. 11: 1433-1452.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert